Christopher R. Cline is CFO at Travere Therapeutics, Inc. (TVTX). They have made 16 open-market trades across 1 company since 2023, most recently 2026-09-15.
CIK 0001943192
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 16 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| TVTX | 87,508 | $4.3M |
Shares reported on the most recent Form 4, priced at the 2026-09-17 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TVTX | SELL · 10b5-1 | 2026-09-15 | 2026-09-17 | $62.34 | $3.1M | -7.0% | — | — |
| TVTX | SELL | 2026-09-02 | 2026-09-03 | $66.37 | $43K | -4.1% | -12.8% | — |
| TVTX | SELL · 10b5-1 | 2026-05-05 | 2026-05-06 | $46.31 | $115K | -5.7% | +0.6% | +23.2% |
| TVTX | SELL · 10b5-1 | 2026-04-13 | 2026-04-15 | $41.91 | $349K | +2.5% | +6.9% | +43.3% |
| TVTX | SELL · 10b5-1 | 2026-02-04 | 2026-02-05 | $32.19 | $56K | -6.8% | -3.1% | +49.6% |
| TVTX | SELL | 2026-02-03 | 2026-02-03 | $32.12 | $233K | -15.2% | -16.7% | +37.0% |
| TVTX | SELL · 10b5-1 | 2025-12-01 | 2025-12-03 | $35.01 | $700K | +0.9% | +14.7% | -17.9% |
| TVTX | SELL · 10b5-1 | 2025-09-03 | 2025-09-05 | $18.51 | $11K | +9.4% | +20.9% | +63.4% |
| TVTX | SELL · 10b5-1 | 2025-08-27 | 2025-08-28 | $17.31 | $8K | +53.6% | +35.2% | +103.9% |
| TVTX | SELL | 2025-05-05 | 2025-05-05 | $21.05 | $38K | +0.7% | -27.6% | -24.0% |
| TVTX | SELL | 2025-04-11 | 2025-04-14 | $13.14 | $631 | +24.9% | +43.8% | +15.3% |
| TVTX | SELL | 2025-02-03 | 2025-02-04 | $20.12 | $209K | +8.8% | -10.1% | +1.7% |
| TVTX | SELL | 2025-01-22 | 2025-01-23 | $18.94 | $16K | +0.7% | +1.3% | -20.3% |
| TVTX | SELL | 2024-09-09 | 2024-09-09 | $11.52 | $29K | +16.7% | +36.4% | +45.5% |
| TVTX | SELL | 2024-09-04 | 2024-09-05 | $9.51 | $5K | +33.3% | +41.3% | +79.4% |
| TVTX | SELL | 2024-04-11 | 2024-04-12 | $6.74 | $364 | -13.9% | +0.2% | +54.7% |
| TVTX | SELL | 2024-02-01 | 2024-02-02 | $8.53 | $33K | -0.8% | -1.6% | -26.0% |
| TVTX | SELL | 2024-01-23 | 2024-01-25 | $9.07 | $8K | -5.5% | -12.5% | -40.6% |
| TVTX | SELL | 2023-09-05 | 2023-09-05 | $14.71 | $7K | -4.1% | -44.7% | -56.0% |
| TVTX | SELL | 2023-05-10 | 2023-05-12 | $16.59 | $8K | +6.1% | +8.4% | -0.8% |
| TVTX | SELL | 2023-04-11 | 2023-04-13 | $21.49 | $1K | +1.5% | -21.0% | -25.1% |
| TVTX | SELL | 2023-02-01 | 2023-02-02 | $21.75 | $35K | -7.8% | +0.7% | -28.0% |
| TVTX | SELL | 2023-01-24 | 2023-01-26 | $21.90 | $19K | -0.2% | -0.5% | -5.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.